Berkshire Hathaway Inc. continued to reduce its stake in DaVita, selling an additional 200,010 shares between May 22 and May 27, 2025. This transaction follows previous sales made in February.
The ongoing divestment by Berkshire Hathaway, a major long-term investor, indicates a continued rebalancing of its portfolio. This trend can be a point of observation for other investors monitoring institutional holdings.
While the specific financial details of this particular sale were not disclosed, it contributes to the pattern of Berkshire Hathaway gradually paring down its ownership in the kidney dialysis provider.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.